PAVmed (PAVM) Q2 2026 Earnings Call Transcript
PAVmed (PAVM) reported Q2 2026 GAAP net loss of $5.5M, non-GAAP adjusted loss of $1.7M, and revenue of $33K. Lucid Diagnostics revenue was $1.5M, driven by 2,770 EsoGuard tests. Cash balance was $3.8M. Veris Health aims for 1,000 patients in its registry. PortIO study showed 100% device patency, and FDA submission is targeted for early 2027. Octeris IRB approval is expected in October 2026. The company has $15M in senior secured notes maturing in 2029.
How this was made
The 30-second read
Why it matters
The earnings release underscores cash burn and reliance on upcoming regulatory milestones, which may drive volatility.
Market read
Primary relevance to investors tracking early‑stage medical device and diagnostic companies; limited broader market effect.
What to watch
Potential cash infusion from the $32.5M callable warrants and upcoming senior note refinancing.
Background
PAVmed provided its Q2 2026 business update, detailing financial results and progress on its Veris health monitor, Lucid Diagnostics, and device pipelines.
Ticker impact
Q2 2026 earnings call disclosed GAAP net loss of $5.5M, revenue of $33K, and updates on Veris, Lucid, and device pipelines.
Potential short-term downside pressure due to loss and low revenue; upside if FDA milestones are met.
The company reported a loss and minimal revenue, indicating near‑term weakness, but the announced regulatory timelines could be a catalyst for a rebound.
Market effects
Highlights ongoing funding challenges in the med‑tech/diagnostics sector and the importance of FDA clearance paths.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to niche investors in early‑stage medical device companies.
Counterpoint
If FDA clearance is achieved on schedule, the stock could rally despite current losses.
Key entities
- CompanyPAVmed Inc.
NASDAQ‑listed med‑tech firm reporting Q2 2026 results.
- SubsidiaryLucid Diagnostics
Provides EsoGuard testing; contributes $1.5M revenue.
